Pulmatrix (NASDAQ:PULM) Releases Quarterly Earnings Results, Beats Estimates By $1.71 EPS

Pulmatrix (NASDAQ:PULM) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.71, FiscalAI reports.

Pulmatrix Price Performance

Shares of Pulmatrix stock traded up $0.06 during trading on Friday, hitting $1.57. 2,619 shares of the company’s stock traded hands, compared to its average volume of 42,797. The company has a market cap of $5.73 million, a PE ratio of -1.28 and a beta of 1.91. Pulmatrix has a twelve month low of $1.16 and a twelve month high of $5.50. The firm’s fifty day moving average price is $1.61 and its 200 day moving average price is $1.76.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Pulmatrix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP purchased a new stake in Pulmatrix, Inc. (NASDAQ:PULM) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned about 0.30% of Pulmatrix as of its most recent SEC filing. Institutional investors and hedge funds own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).